ArteraAI Prostate is authorized for use as a tool to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

The firm said that it will use the money for working capital and general corporate purposes, and the raise follows a $3.25 million public offering that closed in May.

NEW YORK – The World Health Organization on Monday released an update to its operational handbook on the diagnosis of tuberculosis that provides laboratory personnel, clinicians, ministries of health, ...

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming, nonetheless, and the industry ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus ...

The South Korean firm said that its CURECA system offers walkaway PCR testing with 24/7 operation without human intervention ...

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.

The laboratory medicine organization is focused on the benefits of using data science within laboratories to more effectively care for patients and track utilization.

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.